The impact of a pharmacist-managed dosage form conversion service on ciprofloxacin usage at a major Canadian teaching hospital: a pre- and post-intervention study

Table 1 Patient demographics

	Phase I Nov. 12, 02 to Nov. 11, 03 (365 days)	Phase II Nov. 12, 03 to Mar. 11, 04 (120 days)
No. of patients	100	100
No. of treatment courses	100	100
Age (yr), median (range)	57 (17–93)	63 (16–91)
Gender, N
Male	45	50
SCr¹ (μmol/L), median (range)	84 (40–541)	89 (35–641)
Length of Stay (d), mean (range)	12 (1–84)	17 (1–165)
*Service Area, N*
General Surgery	31	30
Medicine	22	11
Emergency	15	11
Intensive Care Unit	7	8
Urology	3	12
Other	22²	28³
*Indication, N*
Off-label indications⁴	38	35
Intra-abdominal infection	18	15
Respiratory tract infection	15	16
Urinary tract infection	15	15
Other	14⁵	19⁶

¹ Serum creatinineclosest to start of ciprofloxacin IV treatment.
² Other service areas: Thoracic, Respiratory, Spine, Hematology/BMT, Transplant, Cardiothoracic Surgery, Neurosciences Intensive Care Unit, Cardiology, Day Bed Unit, Same Day Admit Unit, Pre-admission Clinic, Trauma Special Care Unit, Neurosciences, Family Practice, Orthopedics, Vascular, and Gynecology.
³ Other service areas: Thoracic, Spine, Hematology/BMT, Transplant, Cardiology, Day Bed Unit, Same Day Admit Unit, Neurosciences, Family Practice, Vascular, Gynecology, Palliative Care, and Trauma.
⁴ Off-label indicationsrefer to those not approved on the manufacturer's drug monograph.
⁵ Other indications: Empiric therapy in febrile neutropenia, skin and soft tissue, and septicemia.
⁶ Other indications: Empiric therapy in febrile neutropenia, skin and soft tissue, septicemia, and infectious diarrhea.

ISSN: 1472-6963